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Abstract
Cyclosporine A, a drug that inhibits the immune 
response, has been widely used for over 30 years in immu‑
nosuppressive therapy protocols for patient‑recipients of 
the transplanted organs. One of the commonly reported 
side effects of Cyclosporine A is gingival overgrowth, with 
varying degrees of severity, which may interfere with the 
aesthetics and normal functions of the oral cavity. Combi‑
nation with other drugs that can recognize the gum tissue 
as a secondary target organ increases the risk of 
drug‑induced gingival overgrowth. In cases where a lower 
dose of Cyclosporine A or conversion to another immuno‑
suppressive agent (a drug not assigned to such a side 
effect) are not possible, the management of severe gingival 
overgrowth focuses on surgical excision of the excessively 
proliferated gingival tissue. We report the case of a young 
adult with moderate drug‑induced gingival overgrowth, 
the beneficiary of a functional transplanted kidney about 
9 years ago, treated with two immunosuppressives, who 
has undergone gingivectomy with electrocautery, as a nec‑
essary intervention to improve the oral hygiene and to 
avoid worsening of malfunctions in the oral cavity.
Keywords: Cyclosporine A, kidney transplant, gingival 
overgrowth
INTRODUCTION
Drug‑induced gingival overgrowth is a known 
and unwanted side effect, connected with 3 
groups of drugs: anticonvulsants, antihyperten‑
sives, such as calcium channel blockers, and 
immunosuppressives [1]. Cyclosporine A is the 
primary immunosuppressive drug used in the 
last 30 years in organ transplant medicine to pre‑
vent graft rejection by the host. The typical his‑
topathological lesions observed in drug‑induced 
gingival overgrowth are: increasing of the gum 
volume through an abnormal amount of connec‑
tive tissue stroma with overproduction of colla‑
gen and other extracellular matrix proteins, 
GINGIVAL OVERGROWTH INDUCED BY IMMUNOSUPPRESSIVE 
TREATMENT WITH CYCLOSPORINE A AND MYCOPHENOLATE 
MOFETIL IN A PATIENT WITH KIDNEY TRANSPLANT – A CASE 
REPORT AND LITERATURE REVIEW
Daniela TRANDAFIR1, Violeta TRANDAFIR2, D. GOGALNICEANU3
1.  Assist. Prof., PhD, Dept. Oral and Maxillofacial Surgery, Faculty of Medical Dentistry, ”Grigore T. Popa” U.M.Ph., Iasi
2.  Assist. Prof., PhD, Dept. Oral and Maxillofacial Surgery, Faculty of Medical Dentistry, ”Grigore T. Popa” U.M.Ph., Iasi
3.  Prof., PhD, Dept. Oral and Maxillofacial Surgery, Faculty of Medical Dentistry, ”Apollonia” University, Iasi
Contact person: Daniela Trandafir – trandafir.daniela@gmail.com
plasma  cell  infiltration,  increased  number  of 
inflammatory  cells  (macrophages),  increased 
degree of vascularization cell, gum’s covering by 
a parakeratinized epithelium with irregular 
extensions to depth [2]. Since rigorous oral 
hygiene measures were only intended to limit 
the constituted gingival overgrowth and not to 
prevent it, while substitution of the drug‑regime 
is not always a viable solution for the effective 
control of the general status of a patient with 
organ transplant, surgery by gingivectomy rep‑
resents the only therapeutic option for cases 
where severe gingival overgrowth interferes 
dangerously with the normal functions of the 
oral cavity. 
CASE REPORT
A 29 year‑old male patient was referred to the 
Clinics of Oral and Maxillofacial Surgery in Iasi 
for drug‑induced gingival overgrowth, in June 
2013 (fig. 1). At the age of 5 he was diagnosed 
with Alport syndrome or ”hereditary nephritis” 
(a genetic glomerulonephropathy with progres‑
sive evolution to chronic renal failure, hearing 
loss and decreased visual acuity). Arriving in the 
end‑stage of chronic renal failure (at the age of 
18), he was the subject of a 2‑year dialysis pro‑
gram, after which (in 2004), he received a kidney 
transplant (from a clinically dead donor). After 
the kidney transplant procedure, he followed a 
protocol of immunosuppressive therapy with 
SandimmuneR (Cyclosporine A) and CellCeptR 
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hospitalisation in our Clinics were: Sandimmune 
(50 mg), 2 cp per day and CellCept (250 mg), 6 cp 
per day). Since hypertension was secondarily 
diagnosed to nephropathy, he was treated for 2 
years with Isoptin (240 mg), ½ tablet per day and 
Milurit, 100 mg per day. A few months after the 
initiation of immunosuppressive therapy, the 
patient noticed a moderate increase in the fixed 
gum dimensions (especially in the interdental 
papillae) for the frontal dental group, then for 
the lateral one, first on mandibula then on max‑
illary, without functional consequences (there‑
fore, a total of 9 years for gingival overgrowth). 
In the last three months, he noticed an acceler‑
ated growth on the right side of the mandibular 
gingiva in relation to tooth 4.7 (4.7 tooth with 
stretched coronal destruction, grade III of abnor‑
mal tooth mobility and periradicular osteolysis 
visible on ortopantomography). The noticed gin‑
gival overgrowth interests both the vestibular 
and the lingual side of the mandibular arch, 
reaching the occlusal plane in the right side and 
covering 2/3 of crowns height for the rest of the 
dental arch. In the maxillary arch, gingival over‑
growth interested especially the interdental 
papillae and the third of dental crowns height on 
the sides. Orthopantomography osteolysis 
revealed a discrete horizontal generalized oste‑
olysis and a stretched periradicular osteolysis 
in tooth 4.7 (fig. 2). Blood biological explora‑
tions gave the following results: RBC = 3.72 
(4.2‑6x106/μL), Hb = 10.5 (13 to 17 g/dL), Ht = 
32.6 (40‑51%), serum urea = 68 (15‑50 mg/dL), 
serum creatinine = 2.66 (0.7 to 1.2 mg/dL), serum 
total protein = 56 (64‑83/g/L). The surgical treat‑
ment consisted of: 4.7 dental extraction, 2.7 den‑
tal extraction (otherwise unrecoverable), 
gingivectomy using the elecrocautery (both on 
the vestibular and oral side) for 4.8‑3.3 dental 
group, with favorable postoperative evolution 
(fig. 3).
DISCUSSION
In dentistry services, gingival overgrowth is 
one of the most common side effects seen in 
patients with renal transplant and immunosup‑
pressive therapy with cyclosporine A [1].
Compared with the prevalence of gingival 
overgrowth in healthy population, estimated to 
be between 4 to 7.5%, the reported prevalence of 
gingival overgrowth detected after cyclosporine 
A therapy varies between 8‑81% [2]. 
The now widely accepted term ”gingival 
overgrowth” describes the excessive growth of 
the gum region, by increasing both the size 
Fig. 2. Ortopantomography
Fig. 3. Intraoral view 7 days after surgery 
(gingivectomy using the electrocautery)
Fig. 1. Drug‑induced gingival overgrowth 
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(”hypertrophy”) and number (”hyperplasia”) of 
the cellular constituents [3]. As generally known, 
gingival overgrowth can be either hereditary or 
the result of some pathological reactions (leuke‑
mic infiltrates, granulomatous disease, Crohn’s 
disease, sarcoidosis), or a secondary consequence 
of a chronic treatment with drugs from the fol‑
lowing therapeutic classes: anticonvulsants (Phe‑
nytoin), antihypertensive – like calcium channel 
blockers type (Nifedipine, Verapamil, Diltiazem) 
and immunosuppressives (Cyclosporine A) [4]. 
Theoretically, the here presented case shows a 
greater risk of developing gingival overgrowth 
due to the treatment protocol, which included 
three absolutely necessary drugs (two immuno‑
suppressives and a calcium channel blocker), 
known as inducing this side effect.
The immunosuppressive therapy is indicated 
in autoimmune diseases (psoriasis, systemic ery‑
thematosus lupus, rheumatoid arthritis, multiple 
sclerosis), but also to prevent rejection of the 
transplanted solid organ (kidney, liver, heart or 
other organs) [5]. Kidney transplantation (the 
most common transplanted organ), performed 
worldwide for about 60 years, is considered 
today to be a routine therapy for the manage‑
ment of irreversible renal failure, even if, after 
this procedure, it is mandatory to start the immu‑
nosuppressive therapy to create conditions for 
lymphocytic inactivity, thus avoiding rejection 
of the transplanted kidney [1].
Cyclosporine A was the first immunosuppres‑
sive drug used to prevent organ rejection and it 
is still the main immunosuppressive agent used 
for this purpose [6]. The clinical use of Cyclo‑
sporine A is often complicated by several 
well‑documented side effects, including: nephro‑
toxicity, hepatotoxicity, neurotoxicity, diabetes, 
epilepsy, tremors, hypertension, gallbladder 
stones, hirsutism (hypertrichosis), impaired bone 
metabolism. Gingival overgrowth, the lingual 
fungiform papillae hipertrophy and hairy leuko‑
plakia have been repeatedly reported in the oral 
cavity [7].
In gingival overgrowth, gum size may be 
affected in varying degrees (from mild to severe 
ones) so that, besides the aesthetic damage, this 
unwanted side effect of the immunosuppressive 
drugs may interfere with the normal functions 
of the oral cavity. Gingival overgrowth begins at 
the interdental papilla (especially in the anterior 
region, on the vestibular side), evolves symmet‑
rically, limited to the fixed gum or gets extended 
to dental crowns, and can cause delayed erup‑
tion and/or ectopic teeth, dental malocclusions, 
speech disorders and, last but not least, difficulty 
in maintaining oral hygiene ‑ leading to increased 
susceptibility to infections, cavities and perio‑
dontal diseases [8]. Gingival overgrowth has not 
been generally described in patients with eden‑
tulous or edentulous spaces, but sporadic reports 
of excessively increased gingival areas in eden‑
tulous patients with organ transplants were 
associated with microinjuries caused by remov‑
able dentures or Candida infections [1]. In the 
reported case, the proliferated gum size was 
moderate for jaw and severe for mandible (where 
it revealed certain areas of adjacent gingival 
inflammation and periodontal disease).
Cyclosporine A‑induced gingival overgrowth 
has a multifactorial etiology, the risk factors 
incriminated for the increased incidence and 
severity of gum disease including: age at the time 
of transplant (inverse relationship), sex of the 
patient (men being three times more susceptible 
to this side effect), duration of treatment and 
dosage used (directly proportional relationship), 
drug concentration in serum and saliva, combi‑
nation with other drugs (Cyclosporin A and 
Nifedipine combination significantly increases 
the incidence of gingival overgrowth), genetic 
predisposition and oral hygiene [1,2,9‑11]. There 
is a wide (intra‑ and interindividual) variability 
in terms of susceptibility to Cyclosporine 
A‑induced gingival overgrowth, this change 
being acknowledged, in principle, in over 70% of 
adult patients with organ transplantation, pos‑
sibly even a few months after starting medica‑
tion [12]. In this context, the reported case is 
distinguished by the following: hereditary kid‑
ney disease, kidney transplant performed at 
young age, immunosuppressive protection con‑
trolled by two drugs, hypertension secondarily 
to renal disease controlled by a drug with risk of 
gingival overgrowth, poor oral hygiene and con‑
secutive periodontal disease, long‑evolving gum 
proliferation.
Different therapeutic approaches have been 
proposed for the management of drug‑induced 186 volume 3 • issue 3 July / September 2013 •  pp. 183-187 
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gingival overgrowth, such as: intensive oral 
hygiene programs, alternative pharmacological 
therapies and surgery to reduce the gingival size 
and reshape the gingival contour [1‑3,6,8]. It is 
generally acknowledged that severe oral hygiene 
measures can reduce the established gingival 
overgrowth, even if they cannot stop its develop‑
ment, highlighting the role of dental plaque and 
gingival inflammation in initiating changes in 
drug‑induced gingival overgrowth [8]. A 
decrease in the Cyclosporine A dose appeared as 
beneficial to gingival overgrowth, but, often, the 
nature of organ transplantation does not allow 
this course of treatment or an alternative drug 
therapy. In some selected cases (e.g., if severe 
gingival overgrowth relapses after gingivec‑
tomy), an alternative to Cyclosporine A can be a 
new type of immunosuppressive drug: Tacroli‑
mus (PrografR), Rapamycin, Mycophenolate 
mofetil (CellCeptR). Tacrolimus is an immuno‑
suppressive with a different toxicity profile in 
comparison with Cyclosporine A and it is not 
associated with gingival overgrowth [13‑18]. A 
severe gingival overgrowth, with aesthetic defi‑
ciencies  involving  or  significantly  interfering 
with the oral cavity functions (mastication, 
speech), brings into question excision of the 
gums grown in size (gingivectomy), a procedure 
that may appear as an inevitable choice, only 
after a thorough assessment (due to the risk of 
bleeding) [19]. The management in the reported 
case adopted a solution of necessity, caused by 
the impossibility of changing the treatment pro‑
tocol, so that a gingivectomy with gingival con‑
tour restoration using electrocautery, for 
reducing to a minimum the risk of local bleeding, 
was performed.
CONCLUSIONS
Gingival overgrowth is a side effect of the 
long‑term administration of immunosuppres‑
sives (Cyclosporine A and Mycophenolate 
mofetil) combined with calcium channel block‑
ers (Isoptin), being also influenced by other risk 
factors (dental plaque and adjacent gingival 
inflammation).
Surgical excision of gingival overgrowth areas 
and gingival contour remodeling are required 
when this side effect causes aesthetic and func‑
tional impairments.
The gingivectomy performed with electrocau‑
tery is an effective method for removing the 
excessively increased gum, decreasing the risk of 
intraoperative bleeding.
References
1.  Ciavarella D., Guiglia R., Campisi G. et al. Update on 
gingival overgrowth by Cyclosporine A in renal trans‑
plants, Med Oral Patol Oral Cir bucal 2007; 12:E19‑25.
2.  Mishra M.B., Khan Z.Y., Mishra S. Gingival over‑
growth and drug association: a review, Indian J Med Sci 
2011; 65:73‑82.
3.  Bhardwaj A., Bhardwaj V.S. Gingival enlargement 
induced by anticonvulsants, calcium channel blockers 
and immunosuppressants: a review, Int Research J 
Pharmacy 2012; 3(7):116‑119.
4.  Marshall R.I., Bartold P.M. A clinical review of drug 
induced gingival overgrowth, Aust Dent J 1999; 
44:219‑232.
5.  Pernu H.E., Pernu L.M.H., Huttunen K.R.H. et al. 
Gingival overgrowth among renal transplant recipients 
related to immunosuppressive medication and possible 
local background factors, J Periodontol 1992;63:548‑553.
6.  Hernández G., Arriba L., Frias M.C. et al. Conversion 
from Cyclosporin A to Tacrolimus as a non‑surgical 
alternative to reduce gingival enlargement: a prelimi‑
narycase series, J Periodontol 2003; 74:1816‑1823.
7.  Paul L.C. Overview of side effects of immunosuppressive 
therapy, Transplant Proc 2001; 33:2089‑2091.
8.  Taylor B.A. Management of drug‑induced gingival 
enlargement, Aust Prescr 2003; 26:11‑13.
9.  Kataoka M., Kido J., Shinohara Y., Nagata T. 
Drug‑induced gingival overgrowth: a review, Biol 
Pharm Bull 2005; 28:1817‑1821. 
10. Hallmon W.W., Rossmann J.A. The role of drugs in 
the pathogenesis of gingival overgrowth. A collective 
review of current concepts, Periodontol 2000 1999; 
21:176‑196.
11.  Seymour R.A., Heasman P.A. Drugs and the periodon‑
tium, J Clin Periodontol 1988; 15:1‑16.
12.  Daley T.D., Wysocki G.P., Day C. Clinical and phar‑
macologic correlations in Cyclosporine–induced gingival 
hyperplasia, Oral Surg Oral Med Oral Pathol 1986; 
62:417‑421.
13.  James J.A., Jamal S., Hull P.S. et al. Tacrolimus is not 
associated with gingival overgrowth in renal transplant 
patients, J Clin Periodontol 2001; 28:848‑852.
14.  Hernández G., Arriba L., Lucas M., de Andrés A. 
Reduction of severe gingival overgrowth in a kidney 
transplant patient by replacing Cyclosporin A with Tac‑
rolimus, J Periodontol 2000; 71:630‑636.
15.  James J.A., Boomer S., Maxwell A.P. et al. Reduction 
in gingival overgrowth associated with conversion from International Journal of Medical Dentistry 187
GINGIVAL OVERGROWTH INDUCED BY IMMUNOSUPPRESSIVE TREATMENT WITH CYCLOSPORINE A 
AND MYCOPHENOLATE MOFETIL IN A PATIENT WITH KIDNEY TRANSPLANT 
cyclosporin A to tacrolimus, J Clin Periodontol 2000; 
27:147‑148. 
16. Thorp M., DeMattos A., Bennet W., Barry J., Nor‑
man D. The effect of conversion from cyclosporine to 
tacrolimus on gingival hyperplasia, hirsutism and cho‑
lesterol, Transplantation 2000; 69:1218‑1224.
17.  Kennedy D.S., Linden G.J. Resolution of gingival over‑
growth following change from cyclosporin to tacrolimus 
therapy in a renal transplant patient, J Ir Dent Assoc 
2000; 46:3‑4.
18. Ponticelli C., Tarantino A. From Cyclosporine to the 
future, Transplant Proc 2004; 36:557S‑560S.
19.  Hedge R., Kale R., Jain A.S. Cyclosporine and Amlodi‑
pine induced severe gingival overgrowth – etiopathogen‑
esis and management of a case with electrocautery and 
carbon‑dioxide (CO2) laser, J Oral Health Comm Dent 
2012; 6(1):34‑42.